Indoco Remedies Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CANAGLIFLOZIN, with a corresponding US DMF Number 30951.
Remarkably, this DMF maintains an Active status since its submission on October 18, 2016, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 05, 2017, and payment made on September 28, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II